登录 | 注册    关注公众号  
微信公众号
搜索
 > 【VEGF R3】

VEGF R3信息

英文名称:Vascular endothelial growth factor receptor 3
中文名称:血管内皮细胞生长因子受体3
靶点别称:LMPHM1,Primary Congenital Lymphedema,Fms Related Receptor Tyrosine Kinase 4,VEGF Receptor-3,Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 4,VEGFR3,VEGFR-3,FLT4,Vascular endothelial growth factor receptor 3,Fms Related Tyrosine Kinase 4,Tyrosine-Protein Kinase Receptor FLT4,Fms-Like Tyrosine Kinase 4,FLT-4,Fms-Related Tyrosine Kinase 4,LMPH1A,FLT41,PCL,Vascular Endothelial Growth Factor Receptor-3,CHTD7
上市药物数量:12
临床药物数量:15
最高研发阶段:批准上市

VEGF R3分子别名

Flt-4,FLT4,LMPH1A,PCLFLT41,VEGFR3,VEGFR-3,FLT-4,FLT-41,FLT41,PCL

VEGF R3分子背景

Vascular endothelial growth factor receptor 3 (VEGF R3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). VEGF R3 mediates lymphangiogenesis in response to VEGF-C and VEGF-D. VEGF R3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGF R3 may be important for lymph angiogenesis.

VEGF R3上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

VEGF R3临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定